Metopimazine Sans Sucre Viatris Conseil (Metopimazine)

Metopimazine blocks dopamine D2 receptors in the chemoreceptor trigger zone of the medulla, which reduces the neural signals that initiate vomiting. It also antagonizes muscarinic and histamine receptors, providing additional suppression of the vomiting centre and vestibular inputs.

The dosage of Metopimazine Sans Sucre Viatris Conseil is determined by the prescribing clinician based on the patient’s age, weight, severity of symptoms, and clinical setting. Only a qualified health professional should set the dose and frequency.

Safety data for Metopimazine in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any possible risk to the fetus or infant, and this decision must be made by the treating physician.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Metopimazine belongs to the phenothiazine class, which primarily blocks dopamine receptors, whereas many alternatives such as ondansetron target serotonin receptors. Phenothiazines may cause more sedation and extrapyramidal effects, but they are effective for dopamine‑mediated nausea, especially in postoperative settings.

Store the product at ambient temperature, preferably below 25 °C. Keep it in the original packaging to protect it from moisture and light, and ensure the container is tightly closed to maintain product stability.

Metopimazine Sans Sucre Viatris Conseil is taken orally. The tablet (or oral formulation) should be swallowed with water, preferably on an empty stomach unless otherwise directed by the prescriber. Follow the specific instructions provided by the healthcare professional.

Serious adverse reactions can include extrapyramidal symptoms such as dystonia or akathisia, neuroleptic malignant syndrome, severe hypotension, and cardiac arrhythmias. Patients should be monitored closely for these events, and treatment should be stopped immediately if they occur.

Metopimazine is contraindicated in individuals with known hypersensitivity to phenothiazine compounds. Caution is advised for patients with severe hepatic or renal impairment, uncontrolled cardiovascular disease, or a history of extrapyramidal disorders. The prescriber should evaluate each patient’s medical history before initiating therapy.